Top

Published in:

01-12-2009 | Translational Research and Biomarkers

IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis

Authors: Dawei Li, MD, PhD, Dongwang Yan, MD, PhD, Huamei Tang, MD, Chongzhi Zhou, MD, PhD, Junwei Fan, MD, PhD, Shuxia Li, MD, PhD, Xiaoliang Wang, MD, PhD, Jun Xia, MD, PhD, Fei Huang, MD, Guoqiang Qiu, MD, Zhihai Peng, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2009

Abstract

Background

Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) plays a vital role in carcinogenesis; however, its significance and prognostic value in colon cancer remain unclear.

Methods

In this study, a tissue microarray (TMA) containing 203 samples of primary colon cancer was assessed for IMP3 expression by immunohistochemistry. The TMA included 66 lymph node metastasis (LNM) samples. The mRNA and protein expression levels of IMP3 were evaluated by reverse transcription-PCR and Western blot analysis, respectively.

Results

Cytoplasmic immunoreactivity of IMP3 was significantly higher in LNM (93%) than in primary colon cancer (65%) or normal mucosa (3.9%). Increased IMP3 levels were significantly correlated with higher clinical stage, T classification, LNM, presence of distant metastasis, and Ki-67 positivity. IMP3 was up-regulated in colon cancer compared with paired normal colonic mucosa. IMP3 expression was associated with an 11-fold increased risk of distant metastases (hazard ratio (HR) 10.7; 95% confidence interval (CI) 3.3–34.5; P < 0.0001). Patients with IMP3-positive localized tumors had lower 5-year disease-free survival (DFS) (HR 2.87; 95% CI 1.65–4.98; P < 0.0001) and overall survival (OS) (HR 4.2; 95% CI 2.51–10.17; P < 0.0001) than those with IMP3-negative tumors. Multivariate survival analysis showed that IMP3 was an independent prognostic marker for DFS (HR 1.92; 95% CI 1.06–3.47; P = 0.03) and OS (HR 2.37; 95% CI 1.2–4.7; P = 0.014).

Conclusions

IMP3 may play an important role in colon cancer progression and could serve as a prognostic biomarker to identify patients at risk of developing metastasis or recurrence after colonectomy.

Available only for authorised users

Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 1 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–21.CrossRefPubMed

Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–90.CrossRefPubMed

Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303.CrossRefPubMed

Fan J, Peng Z, Zhou C, et al. Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. Cancer. 2008;113:266–75.CrossRefPubMed

Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262–70.PubMed

Gress TM, Mueller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene. 1996;13:1819–30.PubMed

Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J. H19 RNA binds four molecules of insulin-like growth factor II mRNA binding protein. J Biol Chem. 2000;275:29562–9.CrossRefPubMed

Doyle GA, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD, Ross J. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res. 1998;26:5036–44.CrossRefPubMed

Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517–24.CrossRefPubMed

10.

Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95–9.CrossRefPubMed

11.

Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49–54.CrossRefPubMed

12.

Hammer NA, Hansen TO, Byskov AG, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 2005;130:203–12.CrossRefPubMed

13.

Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant’Agnese PA, Wang HL, Xu H. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 2007;38:1178–83.CrossRefPubMed

14.

Gu L, Shigemasa K, Ohama K. Increased expression of IGF II Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol. 2004;24:671–8.PubMed

15.

Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188–95.CrossRefPubMed

16.

Sojka KM, Spaulding BS, Nielsen GK, Dinnogen SA, Welcher R. Immunoreactivity of anti-L523S on normal and malignant lung pleural tissue biopsies. Mod Pathol. 2006;18:288A.

17.

Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007;38:555–63.CrossRefPubMed

18.

Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556–64.CrossRefPubMed

19.

Istvanic S, Fanger GR, Fraire AE, et al. Spectrum of KOC (K homology domain containing protein over-expressed in cancer) immunostaining among carcinomas of different sites. Mod Pathol. 2005;18:298A–9A.

20.

Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008;21:431–7.CrossRefPubMed

21.

Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3 A novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304–15.CrossRefPubMed

22.

Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008;112:1471–9.CrossRefPubMed

23.

Mueller F, Bommer M, Lacher U, et al. KOC is a novel molecular indicator of malignancy. Br J Cancer. 2003;88:699–701.CrossRefPubMed

24.

O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.PubMedCrossRef

25.

Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer. 2008;112:2740–8.CrossRefPubMed

26.

Hansen TV, Hammer NA, Nielsen J, et al. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol. 2004;24:4448–64.CrossRefPubMed

27.

Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer. 2008;114:49–56.CrossRefPubMed

28.

Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008;22:308–21.CrossRefPubMed

29.

Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J, Nielsen FC. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006;25:1456–68.CrossRefPubMed

30.

Li L, Xu H, Spaulding BO, et al. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol. 2008;39:1205–11.CrossRefPubMed

31.

Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701–6.CrossRefPubMed

Title: IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis
Authors: Dawei Li, MD, PhD
Dongwang Yan, MD, PhD
Huamei Tang, MD
Chongzhi Zhou, MD, PhD
Junwei Fan, MD, PhD
Shuxia Li, MD, PhD
Xiaoliang Wang, MD, PhD
Jun Xia, MD, PhD
Fei Huang, MD
Guoqiang Qiu, MD
Zhihai Peng, MD, PhD
Publication date: 01-12-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0648-5

At a glance: The STEP trials

Springer Medicine

IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2009

Intramucosal Carcinoma on Biopsy Reliably Predicts Invasive Colorectal Cancer

Better 5-Year Survival Rate Following Curative Gastrectomy in Overweight Patients

Correlation of CD133, OCT4, and SOX2 in Rectal Cancer and Their Association with Distant Recurrence After Chemoradiotherapy

Surgical Resection Versus Laparoscopic Radiofrequency Ablation in Patients With Hepatocellular Carcinoma and Child-Pugh Class A Liver Cirrhosis

Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in the Treatment of Stage I Endometrial Cancer: Results From the ILIADE Randomized Study

Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular Carcinomas